MX358439B - Heparinas con baja actividad anticoagulante. - Google Patents

Heparinas con baja actividad anticoagulante.

Info

Publication number
MX358439B
MX358439B MX2014006956A MX2014006956A MX358439B MX 358439 B MX358439 B MX 358439B MX 2014006956 A MX2014006956 A MX 2014006956A MX 2014006956 A MX2014006956 A MX 2014006956A MX 358439 B MX358439 B MX 358439B
Authority
MX
Mexico
Prior art keywords
low anticoagulant
anticoagulant heparins
antifactor
activity
less
Prior art date
Application number
MX2014006956A
Other languages
English (en)
Other versions
MX2014006956A (es
Inventor
Hans-Peter Ekre
Ulf Lindahl
Erik Holmer
Per-Olov Eriksson
Anna Leitgeb
Stefania Tidia
Lino Liverani
Mats Wahlgren
Original Assignee
Modus Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modus Therapeutics Ab filed Critical Modus Therapeutics Ab
Publication of MX2014006956A publication Critical patent/MX2014006956A/es
Publication of MX358439B publication Critical patent/MX358439B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una heparina modificada químicamente con una actividad de antifactor II inferior a 10 UI/mg, una actividad de antifactor Xa inferior a 10 UI/mg y un peso molecular promedio (Mw) entre aproximadamente 6,5 y aproximadamente 9,5 kDa. También se divulga un procedimiento de preparación de heparina y su uso médico, incluyendo el tratamiento del paludismo.
MX2014006956A 2011-12-19 2012-12-19 Heparinas con baja actividad anticoagulante. MX358439B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE2011/051538 WO2013095215A1 (en) 2011-12-19 2011-12-19 Low anticoagulant heparins
PCT/SE2012/051428 WO2013095276A1 (en) 2011-12-19 2012-12-19 Low anticoagulant heparins

Publications (2)

Publication Number Publication Date
MX2014006956A MX2014006956A (es) 2014-10-17
MX358439B true MX358439B (es) 2018-08-21

Family

ID=48668926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006956A MX358439B (es) 2011-12-19 2012-12-19 Heparinas con baja actividad anticoagulante.

Country Status (26)

Country Link
US (2) US9480701B2 (es)
EP (2) EP2794666B1 (es)
JP (2) JP6703806B2 (es)
CN (1) CN104053675B (es)
AU (1) AU2012354226B2 (es)
BR (1) BR112014014673B1 (es)
CA (2) CA2856918C (es)
CY (2) CY1120194T1 (es)
DK (2) DK2794666T3 (es)
ES (2) ES2669055T3 (es)
HK (2) HK1199893A1 (es)
HR (2) HRP20180726T1 (es)
HU (2) HUE037554T2 (es)
IL (1) IL232903A (es)
IN (1) IN2014MN01056A (es)
MX (1) MX358439B (es)
MY (1) MY170069A (es)
NO (2) NO2794666T3 (es)
PH (1) PH12014501387A1 (es)
PL (2) PL2794667T3 (es)
PT (2) PT2794667T (es)
RS (2) RS57213B1 (es)
SI (2) SI2794667T1 (es)
TN (2) TN2014000236A1 (es)
WO (3) WO2013095215A1 (es)
ZA (1) ZA201403654B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56874B1 (sr) 2011-12-19 2018-04-30 Dilafor Ab Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
EP2965764A1 (en) * 2014-07-11 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating vaso-occlusive crisis
WO2015165944A1 (en) * 2014-04-30 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating vaso-occlusive crisis
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
US20210052779A1 (en) * 2018-04-13 2021-02-25 University Of Virginia Patent Foundation Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels
CN109481692A (zh) * 2018-11-30 2019-03-19 东南大学 一种青蒿琥酯肝素衍生物及其药物组合物和应用
WO2023239711A1 (en) * 2022-06-06 2023-12-14 Ihp Therapeutics Inc. Chemically modified heparin
CN115448994B (zh) * 2022-09-28 2023-08-01 山东大学 一种可中和抗凝低分子量肝素及其制备方法和应用
WO2024072942A2 (en) * 2022-09-29 2024-04-04 Adora Animal Health Corporation Skin penetrating formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
GB2625581A (en) 2022-12-21 2024-06-26 Modus Therapeutics Ab New medical use
GB2627263A (en) * 2023-02-17 2024-08-21 Modus Therapeutics Ab New medical use
WO2024170746A1 (en) 2023-02-17 2024-08-22 Modus Therapeutics Ab New medical use of sevuparin in the treatment of endotoxemia

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
DE68906345T2 (de) * 1988-10-07 1993-10-28 Hoechst Ag Antimalariazusammenstellungen, gebrauchmachend von Quinidin, Artemisinin und ihren Derivaten.
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
AU5442594A (en) 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
GB2299998B (en) * 1995-03-31 1997-03-26 Hamilton Civic Hospitals Res Compositions for inhibiting thrombogenesis
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
CA2240328A1 (en) 1996-10-15 1998-04-23 Toray Industries, Inc. Cervical canal maturing agent
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
JP3342007B2 (ja) * 1997-11-20 2002-11-05 郁男 山科 低分子ヘパリン修飾体及び皮膚潰瘍治療剤
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
WO1999043714A1 (fr) 1998-02-26 1999-09-02 Seikagaku Corporation Nouveaux derives de polysaccharide, leur procede de production, et compositions medicinales contenant ces nouveaux derives comme principe actif
US6028061A (en) * 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
KR20010030803A (ko) * 1998-07-31 2001-04-16 야마야 와따루 신규 글리코사미노글리칸 및 이를 함유하는 의약 조성물
MXPA02000142A (es) * 1999-06-30 2003-07-21 Hamilton Civic Hospitals Res Composiciones de heparina que inhiben los factores de coagulacion asociados con el coagulo.
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
CA2422059C (en) * 2000-09-12 2012-05-15 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
EP1542704A1 (en) * 2002-04-18 2005-06-22 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
ES2370729T3 (es) * 2004-05-11 2011-12-22 Egalet Ltd. Forma farmacéutica hinchable que comprende goma gellan.
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) * 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
JP2009507209A (ja) * 2005-07-22 2009-02-19 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア ヘパリン組成物およびセレクチン阻害
CA2616230A1 (en) 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
CA2652205A1 (en) * 2006-05-25 2007-12-06 Mallik Sundaram Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2205642B1 (en) * 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
CN102177180A (zh) * 2008-04-04 2011-09-07 犹他州大学研究基金会 烷基化半合成的糖胺聚糖醚及其制备和使用方法
US20110206770A1 (en) * 2008-07-25 2011-08-25 Alphapharm Pty. Ltd. Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns
EP2419736B1 (en) * 2009-04-16 2014-01-29 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
AU2010268756A1 (en) * 2009-06-30 2012-01-19 The Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
RS56874B1 (sr) 2011-12-19 2018-04-30 Dilafor Ab Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba
RU2014143008A (ru) 2012-03-26 2016-05-20 Дилафор Аб Способ лечения остановки родов
RU2014143017A (ru) 2012-03-26 2016-05-20 Дилафор Аб Препараты для индукции родов

Also Published As

Publication number Publication date
HUE037555T2 (hu) 2018-09-28
PT2794667T (pt) 2018-05-16
TN2014000237A1 (en) 2015-09-30
JP2015500387A (ja) 2015-01-05
US9480702B2 (en) 2016-11-01
CY1120197T1 (el) 2018-12-12
DK2794666T3 (en) 2018-04-23
HK1200471A1 (en) 2015-08-07
ZA201403654B (en) 2017-08-30
IN2014MN01056A (es) 2015-05-01
MX2014006956A (es) 2014-10-17
NO2794667T3 (es) 2018-07-21
EP2794666B1 (en) 2018-02-21
IL232903A0 (en) 2014-07-31
PH12014501387B1 (en) 2014-09-22
EP2794666A1 (en) 2014-10-29
TN2014000236A1 (en) 2015-09-30
HRP20180725T1 (hr) 2018-06-29
JP6703806B2 (ja) 2020-06-03
HUE037554T2 (hu) 2018-09-28
EP2794667A1 (en) 2014-10-29
ES2668273T3 (es) 2018-05-17
CY1120194T1 (el) 2018-12-12
NZ625096A (en) 2016-07-29
NO2794666T3 (es) 2018-07-21
AU2012354226A1 (en) 2014-06-05
EP2794667B1 (en) 2018-02-21
CA2856477A1 (en) 2013-06-27
HK1199893A1 (en) 2015-07-24
RS57214B1 (sr) 2018-07-31
AU2012354226B2 (en) 2017-01-12
EP2794667A4 (en) 2015-07-22
DK2794667T3 (en) 2018-04-23
HRP20180726T1 (hr) 2018-06-15
PL2794666T3 (pl) 2018-08-31
PH12014501387A1 (en) 2014-09-22
BR112014014673A2 (pt) 2017-06-13
WO2013095277A1 (en) 2013-06-27
SI2794667T1 (en) 2018-06-29
ES2669055T3 (es) 2018-05-23
WO2013095276A1 (en) 2013-06-27
SI2794666T1 (en) 2018-06-29
PL2794667T3 (pl) 2018-09-28
CN104053675A (zh) 2014-09-17
MY170069A (en) 2019-07-03
RS57213B1 (sr) 2018-07-31
CA2856918C (en) 2017-07-04
EP2794666A4 (en) 2015-07-22
WO2013095215A1 (en) 2013-06-27
JP2018154848A (ja) 2018-10-04
US9480701B2 (en) 2016-11-01
US20140364369A1 (en) 2014-12-11
US20150031638A1 (en) 2015-01-29
IL232903A (en) 2017-02-28
BR112014014673B1 (pt) 2021-02-17
CA2856918A1 (en) 2013-06-27
CA2856477C (en) 2017-06-27
PT2794666T (pt) 2018-05-09
CN104053675B (zh) 2016-10-12
BR112014014673A8 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
PH12014501387A1 (en) Low anticoagulant heparins
DK2794665T3 (da) Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
MX363923B (es) Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.
BR112015013774A2 (pt) membrana de hidrogel para prevenção de adesão
EA201390600A1 (ru) Терапевтические наночастицы с сополимерами с большим молекулярным весом
UA113005C2 (uk) Біотехнологічний хондроїтин-6-сульфат з низькою молекулярною масою для запобігання остеоартриту
PH12014502680A1 (en) Polysaccharide compositions and methods of use
PH12016501190B1 (en) Substituted piperidinyl-tetrahydroquinolines
WO2018056937A3 (en) Nanofibrous adhesion barrier
MX2019009711A (es) Mejoras en o con respecto a compuestos organicos.
FR2978664B1 (fr) Composition antiseptique
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
MX347620B (es) Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica.
JP2007126453A5 (es)
MY174829A (en) Durable treatment with 4-aminopyridine in patients with demyelination
TR201908669T4 (tr) N-desülfatlanmış glikozaminoglikanların türevleri ve ilaç olarak kullanımı.
RU2016116786A (ru) Иммуностимулятор
MX349595B (es) Fibras, proceso para producir las fibras y aposito para heridas que las incorpora.
WO2009137899A3 (en) Sulfated galactans with antithrombotic activity, pharmaceutical composition, method for treating or prophylaxis of arterial or venous thrombosis, method of extraction and use thereof
UA117912C2 (uk) Застосування гепарину або гепарансульфату для лікування післяпологової кровотечі (ппк)
PL391043A1 (pl) Zastosowanie modyfikowanych polisacharydów do neutralizacji heparyny
MX2012006966A (es) Tratamiento de padecimientos mediados por citocina.
WO2012150392A3 (fr) Solution de rincage de greffon ou de tissu et procede de rincage dudit greffon ou tissu avant revascularisation
WO2011155800A3 (ko) 히알루론산의 탈아세틸화 가수분해효소, 및 이에 의해 탈아세틸화된 히알루론산 및 이의 유도체
EA201992048A1 (ru) Новый вязкоупругий раствор и его применение в ревматологии

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: IMPLANTICA PATENT LTD.

FG Grant or registration